B6.129P2-Pik3catm1Bvan/Orl

Status

Available to order

EMMA IDEM:11393
Citation informationRRID:IMSR_EM:11393 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameB6.129P2-Pik3catm1Bvan/Orl
Alternative nameB6.129P2-Pik3catm1(D933A)Bvan/J
Strain typeTargeted Mutant Strains : Point mutation
Allele/Transgene symbolPik3catm1Bvan
Gene/Transgene symbolPik3ca

Information from provider

ProviderBart Vanhaesebroeck
Provider affiliationUCL Cancer Institute, University College London
Additional ownerthe University of Edinburgh
Genetic informationKnock-in mice in which the endogenous Pik3ca/p110alpha PI3K gene is mutated so that it now encodes a p110alpha protein with (1) the D933A mutation in the ATP binding site, converting it to a kinase-dead p110alpha protein which is expressed at the same level as the wild-type p110alpha; (2) a C-terminal Myc-epitope tag. Backcrossed onto C57BL/6J background.
Phenotypic informationHomozygous:
Mice are lethal prenatally at E9.5, due to growth and angiogenesis defects.

Heterozygous:
Mice are around 15% smaller and have metabolic phenotypes. Mice show healthy aging in longevity experiments (PMID:23483710).
Breeding historyBackcrossed onto C57BL/6J for more than 10 generations.
References
  • Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.;Foukas Lazaros C, Claret Marc, Pearce Wayne, Okkenhaug Klaus, Meek Stephen, Peskett Emma, Sancho Sara, Smith Andrew J H, Withers Dominic J, Vanhaesebroeck Bart, ;2006;Nature;441;366-70; 16625210
Homozygous fertilenot known
Homozygous viableno
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • abnormal angiogenesis / MGI
  • abnormal retinal vasculature morphology / MGI
  • decreased body length / MGI
  • decreased body weight / MGI
  • polyphagia / MGI
  • postnatal growth retardation / MGI
  • increased circulating insulin level / MGI
  • increased pancreatic beta cell number / MGI
  • decreased lean body mass / MGI
  • fetal growth retardation / MGI
  • decreased skeletal muscle mass / MGI
  • impaired glucose tolerance / MGI
  • insulin resistance / MGI
  • increased circulating leptin level / MGI
  • increased fat cell size / MGI
  • abnormal vascular development / MGI
  • internal hemorrhage / MGI
  • embryonic growth arrest / MGI
  • embryonic growth retardation / MGI
  • abnormal vitelline vascular remodeling / MGI
  • abnormal dorsal aorta morphology / MGI
  • embryonic lethality, complete penetrance / MGI
  • abnormal intersomitic vessel morphology / MGI
  • abnormal perineural vascular plexus morphology / MGI
  • embryonic lethality during organogenesis, complete penetrance / MGI
MGI phenotypes (gene matching)
  • vasculature congestion / MGI
  • abnormal vascular development / MGI
  • abnormal angiogenesis / MGI
  • decreased cell proliferation / MGI
  • decreased body length / MGI
  • decreased body weight / MGI
  • polyphagia / MGI
  • internal hemorrhage / MGI
  • abnormal somite development / MGI
  • decreased embryo size / MGI
  • pale yolk sac / MGI
  • embryonic growth arrest / MGI
  • postnatal growth retardation / MGI
  • abnormal lymphatic vessel morphology / MGI
  • hemorrhage / MGI
  • neoplasm / MGI
  • increased circulating insulin level / MGI
  • abnormal retinal vasculature morphology / MGI
  • no phenotypic analysis / MGI
  • abnormal vitelline vasculature morphology / MGI
  • increased pancreatic beta cell number / MGI
  • decreased lean body mass / MGI
  • abnormal endocardium morphology / MGI
  • embryonic growth retardation / MGI
  • abnormal vitelline vascular remodeling / MGI
  • fetal growth retardation / MGI
  • decreased incidence of tumors by chemical induction / MGI
  • abnormal anterior cardinal vein morphology / MGI
  • abnormal dorsal aorta morphology / MGI
  • decreased skeletal muscle mass / MGI
  • abnormal brain vasculature morphology / MGI
  • impaired glucose tolerance / MGI
  • insulin resistance / MGI
  • abnormal cell physiology / MGI
  • increased circulating leptin level / MGI
  • increased fat cell size / MGI
  • abnormal lymphangiogenesis / MGI
  • mortality/aging / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • neonatal lethality, incomplete penetrance / MGI
  • embryonic lethality, complete penetrance / MGI
  • embryonic lethality during organogenesis, complete penetrance / MGI
  • chylous ascites / MGI
  • abnormal intersomitic vessel morphology / MGI
  • abnormal perineural vascular plexus morphology / MGI

Literature references

  • Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.;Foukas Lazaros C, Claret Marc, Pearce Wayne, Okkenhaug Klaus, Meek Stephen, Peskett Emma, Sancho Sara, Smith Andrew J H, Withers Dominic J, Vanhaesebroeck Bart, ;2006;Nature;441;366-70; 16625210

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).